Bright Minds Biosciences Financials - Benzinga

Bright Minds Biosciences Inc

DRUGNASDAQ

Trade with Public

Trade with Public

$84.41

0.370.44%

Últ. Act.: Aug 19, 3:25 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Bright Minds Biosciences Financials

Bright Minds Biosciences (DRUG) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Crude Oil Down 2%; ISM Services PMI Surges In December

Avi Kapoor

Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results

Avi Kapoor

Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views

Avi Kapoor

Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts

Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.

Juan Spínelli

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More

Biden To Decide On Psychedelic Therapy Bill

Lara Goldstein

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Lara Goldstein

© 2026 Benzinga | All Rights Reserved